Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
CRISPR Stock Debuts, Here's What You Need to Know
http://mney.co/2ehiYS1
Required Please enter the correct value.
Twitter
Stocks: CRSP

CRISPR Stock Debuts, Here's What You Need to Know

By Diane Alter, Contributing Writer, Money Morning • October 19, 2016

View Comments

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

CRISPR stockCRISPR stock debuts this week in one of the most highly anticipated biotech IPOs of the year.

Here's everything investors need to know now...

The IPO market has picked up steam in the last quarter. During Q3, there were 33 new issues to hit the market, according to Renaissance Capital, a manager of IPO-focused ETFs. And there have already been 11 IPOs in October alone.

This week, a tiny biotech company is in the spotlight. Here's a look behind the hype of the CRISPR IPO and CRISPR stock...

What You Need to Know About the CRISPR Stock Debut

  • CRISPR Therapeutics is a leading gene-editing company. It develops transformative gene-based medicines with its proprietary gene-editing platform. Its focus is on the treatment of non-germline cells. It's a similar approach to more traditional and established gene therapy methods.
  • The company has dual headquarters in Switzerland and Cambridge, Mass.
  • CRISPR is short for "clustered regularly interspaced short palindromic repeats." It is pronounced "crisper." The company's researchers are able to permanently modify or "edit" genes in living organisms. In the future, the company hopes to correct mutations, which would allow it to treat certain genetic diseases.
  • CRISPR Therapeutics is offering 4 million shares. The CRISPR stock price is set at $14 a share. That's less than the 4.7 million shares originally planned and below the initial price range of $15 to $18.
  • CRISPR stock will debut Wednesday, Oct. 19. Shares will trade under the ticker CRSP and will be listed on the Nasdaq.
  • CRSP is expected to raise $56 million in its IPO. Citigroup, Piper Jaffrey, and Barclays are the lead underwriters.
  • The biotech company had sales of roughly $2 million for the year ending June 30, 2016. But it recorded an operation loss of nearly $30 million for the first half of 2016.
  • CRSP has collaborations with Bayer AG (OTCMKTS: BAYRY), Vertex Pharmaceutical Inc. (Nasdaq: VRTX), Celgene Corp. (Nasdaq: CELG), and GlaxoSmithKline Plc. (NYSE: GSK). Bayer, Celgene, and Glaxo are key shareholders with stakes of about 8%, 12.4%, and 9.7%, respectively.

CRISPR has been in the spotlight for years since the company has such a revolutionary product.

The company hopes to find cures for conditions like sickle cell disease and better ways to fight certain cancers.

The company is still very early in its development efforts. All of its product candidates are in preclinical development. It will be many years before the company or its collaborators will commercialize a product candidate.

In the meantime, we'll be following up with this company and evaluating CRISPR stock as an investment for our readers at Money Morning.

And for investors looking to profit from the IPO market in 2016, we've found one investment that allows you to profit from the entire IPO market...

Follow us on TwitterĀ @moneymorningĀ and like us onĀ Facebook.

Related Articles:

  • MIT Technology Review: Can CRISPR Save Ben Dupree?
  • Street Insider: CRISPR Therapeutics (CRSP) Prices 4M Common Stock IPO at $14/Share, Below Prior Expectation
  • Fierce Biotech: CRISPR Therapeutics Raises a $56M IPO, but Patent Battles, Potential Stock Drop Looms

Join the conversation. Click here to jump to comments…

Login
guest
guest
1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
cary gibbs
cary gibbs
4 years ago

thanks or the great insightf

0
Reply
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

Ā© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz